Literature DB >> 30452090

Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Sara Lundqvist1, Signe Modvig1, Emilie A Fischer1, Jette L Frederiksen1, Matilda Degn1.   

Abstract

Mouse models of multiple sclerosis (MS) have shown the importance of interleukin-10 (IL-10) -producing regulatory B (Breg) cells in dampening disease activity and inhibiting disease initiation and progression. In MS and other autoimmune diseases decreased frequency and functionality of Breg cells correlate with disease activity and the percentage of IL-10-producing Breg cells decreases during relapse and normalizes in remission. Optic neuritis (ON) is a common first clinical manifestation of MS and IL-10-producing Breg cells may be crucial in the transition from ON to MS, we therefore investigate the frequency and function of Breg cells in ON as a clinical model of early demyelinating disease. B cells were purified from 27 patients with ON sampled close to symptom onset (median 23 days, range 7-41 days) and 13 healthy controls. The B cells were stimulated and cultured for 48 hr with CD40 ligand and CpG before measurement of intracellular IL-10 and the surface markers CD19, CD1d, CD5, CD24, CD38 and CD27 by flow cytometry. The frequency of B-cell subsets was analysed in peripheral blood and cerebral spinal fluid (CSF) of patients. Sixty-five per cent of the IL-10-producing Breg cells co-expressed CD24 and CD38, and only 14% were CD24high  CD27+ , suggesting that the naive B cells are the primary source of IL-10 in the B-cell culture, followed by memory cells in both healthy controls and patients. The frequency of naive CD19+  CD24+  CD38+ Breg cells was higher in patients with ON compared with controls. The ability of Breg cells to produce IL-10 was at normal levels in both ON patients with high risk and those with low risk of progression to MS. We found no correlation between Breg cell function and the presence of brain white matter lesions by magnetic resonance imaging or CSF oligoclonal bands indicative of ON patients carrying a higher risk of conversion to MS. The frequencies of IL-10-producing B cells did not correlate with the conversion to MS at 2-year follow up. Interleukin-10 was primarily produced by naive and memory B cells. The frequency of IL-10-secreting B cells did not correlate with risk factors of MS. Breg cell function at clinical onset of ON is not a determining factor for conversion to MS.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  clinically isolated syndrome; interleukin-10; multiple sclerosis; optic neuritis; regulatory B cells

Mesh:

Substances:

Year:  2018        PMID: 30452090      PMCID: PMC6376272          DOI: 10.1111/imm.13024

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  48 in total

1.  Identifying regulatory B cells (B10 cells) that produce IL-10 in mice.

Authors:  Takashi Matsushita; Thomas F Tedder
Journal:  Methods Mol Biol       Date:  2011

Review 2.  Regulatory B cells: origin, phenotype, and function.

Authors:  Elizabeth C Rosser; Claudia Mauri
Journal:  Immunity       Date:  2015-04-21       Impact factor: 31.745

3.  Memory and naïve B-cell subsets in patients with multiple sclerosis.

Authors:  Masaaki Niino; Makoto Hirotani; Yusei Miyazaki; Hidenao Sasaki
Journal:  Neurosci Lett       Date:  2009-08-08       Impact factor: 3.046

4.  Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis.

Authors:  Laure Michel; Melanie Chesneau; Philippe Manceau; Athenais Genty; Alexandra Garcia; Marion Salou; Annie Elong Ngono; Annaïck Pallier; Marylène Jacq-Foucher; Fabienne Lefrère; Sandrine Wiertlewski; Jean-Paul Soulillou; Nicolas Degauque; David-Axel Laplaud; Sophie Brouard
Journal:  Clin Immunol       Date:  2014-09-28       Impact factor: 3.969

5.  A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand.

Authors:  Avijit Ray; Sreemanti Basu; Calvin B Williams; Nita H Salzman; Bonnie N Dittel
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

6.  Is optic neuritis more benign than other first attacks in multiple sclerosis?

Authors:  Mar Tintoré; Alex Rovira; Jordi Rio; Carlos Nos; Elisensa Grivé; Neus Téllez; Raul Pelayo; Manuel Comabella; Xavier Montalban
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

Review 7.  Rituximab for relapsing-remitting multiple sclerosis.

Authors:  Dian He; Rui Guo; Fubo Zhang; Chao Zhang; Shuai Dong; Hongyu Zhou
Journal:  Cochrane Database Syst Rev       Date:  2013-12-06

8.  CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.

Authors:  Fabian Flores-Borja; Anneleen Bosma; Dorothy Ng; Venkat Reddy; Michael R Ehrenstein; David A Isenberg; Claudia Mauri
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

9.  Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity.

Authors:  Claire I Daien; Sarah Gailhac; Thibault Mura; Rachel Audo; Bernard Combe; Michael Hahne; Jacques Morel
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

10.  Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus.

Authors:  Ji Hyun Sim; Hang-Rae Kim; Soog-Hee Chang; In Je Kim; Peter E Lipsky; Jisoo Lee
Journal:  Arthritis Res Ther       Date:  2015-07-25       Impact factor: 5.156

View more
  2 in total

Review 1.  A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.

Authors:  Lei Zhu; Binyao Chen; Wenru Su
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 2.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.